NCT06605365
Completed
Not Applicable
Ophthalmic Solution in Drye Eye Patients
D&V FARMA srl1 site in 1 country20 target enrollmentSeptember 1, 2021
ConditionsDry Eye Disease (DED)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Dry Eye Disease (DED)
- Sponsor
- D&V FARMA srl
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- TBUT
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
Data analyses and revision of the DED symptoms. A novel ophthalmic solution containing cross-linked CMC (CX-CMC) and Silk Proteins (SP) has been made available on the market.
Both molecules have been widely studied for their viscoelastic and hydrating, and wound healing properties.
This new ophthalmic solution is the first on the market formulated with a CX-CMC and SP.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects affected by dry eye disease
Exclusion Criteria
- •know allergies to CX-CMC
- •know allergies to SP
Outcomes
Primary Outcomes
TBUT
Time Frame: 3 months
Tear Breakup Time
Secondary Outcomes
- OSDI(3 months)
- Wound Healing(30 hours)
- UV and Blue light absorption(0 hours)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Cross-linked Hyaluronic Acid and Coenzyme Q10 in the Treatment of Dry EyeDry Eye SyndromeNCT03074344Azienda Ospedaliera Universitaria Policlinico "G. Martino"40
Completed
Phase 4
The DEPOT Study (Dry Eye Prescription Options for Therapy)Dry EyeNCT04911361Research Insight LLC50
Completed
Not Applicable
Clinical Research of Diquas ophthalmic solution 3% on corneal epithelial barrier function in dry eyeDry eyeJPRN-UMIN000021884Collaborative joint clinical research organized with Kyorin university School of Medicine and Santen Pharmaceutical Co., Ltd.20
Completed
Phase 2
Safety and Efficacy of an Ophthalmic Solution in Dry Eye DiseaseDry Eye DiseaseNCT00758784Bausch & Lomb Incorporated38
Completed
Phase 2
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye DiseaseDry Eye DiseaseNCT00667004Bausch & Lomb Incorporated183